Share on StockTwits

Portola Pharmaceuticals (NASDAQ:PTLA) CEO William Lis sold 30,000 shares of the stock in a transaction that occurred on Thursday, July 3rd. The shares were sold at an average price of $30.41, for a total value of $912,300.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Portola Pharmaceuticals (NASDAQ:PTLA) traded down 0.91% during mid-day trading on Thursday, hitting $30.61. 117,246 shares of the company’s stock traded hands. Portola Pharmaceuticals has a one year low of $19.59 and a one year high of $31.48. The stock’s 50-day moving average is $25. and its 200-day moving average is $25.42. The company’s market cap is $1.259 billion.

Portola Pharmaceuticals (NASDAQ:PTLA) last released its earnings data on Monday, May 12th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by $0.03. The company had revenue of $2.40 million for the quarter, compared to the consensus estimate of $1.81 million. During the same quarter in the previous year, the company posted ($12.94) earnings per share. The company’s revenue for the quarter was down 23.8% on a year-over-year basis. On average, analysts predict that Portola Pharmaceuticals will post $-3.44 earnings per share for the current fiscal year.

Portola Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who has limited or no approved treatment options.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.